INTRODUCTION
Nowadays, the most effective way to manage cardiovascular problems is combination therapy. Serum albumin, the most abundant protein in blood plasma, serves as a depot and transport protein for numerous endogenous and exogenous compounds (Kragh-Hansen, 1981) . The most outstanding property of albumin is its ability to bind reversibly with different ligands including fatty acids, amino acids (tryptophan and cysteine), steroids, metals such as calcium, copper, zinc and numerous pharmaceuticals (He and Carter, 1992) . From different studies, it is known that there are mainly three high affinity drug binding sites on human serum albumin which are generally termed as warfarin, benzodiazepine and digoxin binding sites which are also denoted as site I, site II, site III, respectively (Fehske et al.,1979; Sudlow et al.,1975 , Sudlow et al., 1976 Uddin et al., 2004) . When two or more drugs are administered in any biological system they compete for each other to bind with these binding sites. Problems are created when the concomitantly administered drugs show their affinity to the same binding site (Rahman and Sharker, 2009 ).
In that case, patient may experience mild to severe alteration in action of drugs than that of individual when administered in different time.
Efficacy as well as toxic profile of drug depends largely on its ability to bind with serum protein. The more binding of drug with plasma protein indicates the less free drug in the blood. It is generally assumed that free drug concentration in the blood is responsible for its action on biological system. In most of the cases only a little percentage of drug remains in free form in plasma. So small displacement of drug from plasma protein may result many fold increment in its activity in the biological system (Alam et al., 2008) . The present study has centered mainly on the binding chemistry of amlodipine besylate (calcium channel blocker) and benazepril hydrochloride (angiotensin converting enzyme inhibitor) to BSA. Amlodipine besylate and benazepril hydrochloride are widely used drug for treating hypertension and chest pain (angina). To observe binding chemistry of amlodipine besylate and benazepril hydrochloride on BSA, the association constants as well as the binding sites to Bovine Serum Albumin (BSA) were calculated by scatchard analysis (Scatchard, 1949) at pH 7.4 and 37°C. In this study BSA was used in lieu of HAS (human serum albumin), because of its structural similarity with HSA, low cost and easy availability.
To find out binding sites of amlodipine and benazepril to plasma protein, displacement effect from serum protein upon concurrent administration and suitability for concurrent administration were the main purpose of this study.
MATERIALS AND METHODS

Drugs and Reagents
Experimental drugs amlodipine besylate and benazepril hydrochloride were kind gift from Incepta Pharmaceuticals Ltd, Bangladesh. Probe warfarin sodium and diazepam were collected from Aristo Pharma Ltd, Bangladesh. Methanol and Ethanol used in this experiment were of analytical grade and purchased from Merck K GaA, Germany. Disodium hydrogen phosphate anhydrous (Na 2 HPO 4 ) and potassium dihydrogen phosphate (KH 2 PO 4 ) were purchased from Merck Specialties Pvt. Ltd, India. Ortho-Phosphoric Acid and Acetonitrile (used as mobile phase) were purchased from E. Merck, Darmstadt, Germany. Cellulose membrane dialysis tube (Molecular cut off at 3500 Daltons) was purchased from Medicell Membrane Ltd, 239 Liverpool Road, London. Bovine serum albumin (fatty acid free, fraction V and 96-98%) was purchased from the Lobe Chemie Pvt. Ltd, India. Molecular weight of the protein is approximately 66,210 Dalton with 581 amino acids and 4.7 isoelectric points.
Instruments
UV-VIS Spectrophotometer (UV-1700, Shimadzu, Japan), HPLC system consisting a CMB-20 alit system Controller, two LC-20AT pumps, SIL-20A auto sampler and CTO-10ASVP column oven (Shimadzu, Japan) and Sonicator (PowerSonic505) were used in the study.
Preparation of membrane
Recommended tubing length (9 cm) was calculated based on the desired sample volume and the tubing flat wide. The supplied membrane was cut into small pieces (9 cm in length) and taken in 500 mL beaker containing de-ionized water. The pieces of membranes were immersed beneath the de-ionized water and heated between 65-70 0 C for 10 -12 hours in order to remove sulfur. Hot water was replaced by fresh de-ionized water at every one hour interval for efficient removal of sulfur. The prepared pieces of membrane were kept in a breaker containing fresh deionized water and preserved in a refrigerator (chilling chamber) until use.
Preparation of protein (BSA) solution at pH7.4
To prepare 100 ml of 2 x 10 -5 M solution of BSA 0.133 gm of protein was accurately measured and dissolved in a 100 mL volumetric flask with the previously prepared phosphate buffer solution of pH 7.4. This was done carefully and gently so that it did not produce foam. The protein solution was kept in a refrigerator Until use. After proper mixing absorbance were determined at 241 nm (amlodipine besylate), 239 nm (benazepril hydrochloride), 315 nm (warfarin sodium) and 258.5 nm (diazepam) by a UV spectrophotometer (UV-1700). The standard curve was obtained by plotting the absorbance values against the corresponding concentrations.
Preparation of standard curve
Determination of association constant
Association constant and corresponding binding site (n) of amlodipine besylate and benazepril hydrochloride were determined by scatchard plot method (Scatchard, 1949) M. The seventh test tube containing 5ml BSA and 5ml buffer solution was marked as "control". The solutions were then properly mixed and allowed to stand for 30 minutes in order to ensure maximum binding of amlodipine besylate to BSA. From each of the test tube, 3.5 mL solution was pipetted out and poured into seven previously prepared semi permeable membrane tubes. Two ends of the membrane tubes were folded and fixed with thread so that there was no leakage. The membrane tubes were then immersed in seven separate 50 mL conical flasks containing 20 mL of phosphate buffer solution of pH 7.4. The mouths of the conical flasks were covered by aluminum foil. These conical flasks were then placed in a water bath shaker for dialysis for 12 hours at 37°C and 20 rpm. After completion of dialysis samples were collected from each flask. Free concentrations of amlodipine besylate were measured by UV-spectrophotometer at a wavelength of 241 nm.
Determination of association constant of benazepril hydrochloride bound to BSA at pH 7.4 and 37 °C
Association constant of benazepril hydrochloride was calculated by using the same method as mentioned above. Five mL of 2x10 -5 M solution were taken in each of the seven test tubes and benazepril hydrochloride was added and diluted by buffer solution (up to 10 ml) to make the concentration 2 x10 M. The above method was followed for dialysis upto 12 hours and finally free concentrations of Benazepril HCl were measured by UV-spectrophotometer at a wavelength of 239 nm.
Identification and characterization of binding site of drugs on BSA at pH 7.4 and 37 °C
The specificity and relative strength of binding of a drug to albumin is generally determined by its ability to displace the probes specific for particular sites on albumin. In this study, we examined different site specific probes to advance our understanding of the drug-BSA interaction and characterization of binding sites of the drugs used in the study.
Binding sites of amlodipine besylate and benazepril hydrochloride on BSA were identified by using two site specific probes: warfarin sodium (site-I specific probe) and diazepam (site-II specific probe). In the presence of the mixture of the probe and BSA at a constant ratio (1:1, 1x10
concentrations of drugs were added separately. Free concentrations of the probe and drug were then determined by the equilibrium dialysis method to see whether there was any change in the free concentrations of the probe by the addition of the drug. Samples were analyzed by a validated HPLC method. The mobile phase of the HPLC method was a mixture of acetonitrile-buffer (pH 2.5) (60:40 v/v) which was pumped at a flow rate of 1ml/min through the column (C 18 ; 5μ, 4.6 X 150 mm, Waters, USA) at ambient temperature. Buffer solution was prepared by dissolving 2gm of potassium hydrogen phosphate in HPLC grade water to make a final volume 500 ml. pH was adjusted with ortho-phosphoric acid (pH 2.5). The injection volume was 10μl. The mobile phase was filtered through 0.2μ membrane filter and degassed prior to use suction pump with negative pressure filtration. Concentrations were measured at 248nm by UV detector at a sensitivity of 0.00001. The run time was at 15 minutes and column temperature was maintained at 25°C. Prior to injection of sample, the column was equilibrated for 30 minutes with mobile phase.
Determination of binding site of amlodipine besylate using warfarin sodium as a site-I specific probe M) was added with increasing concentrations into four out of five test tubes containing 1:1 mixture of BSA-Warfarin. The final ratios between amlodipine besylate and protein were 1:1, 2:1, 4:1 and 6:1 and made the final volume by respective buffer solution. Amlodipine besylate was not added in the one test tube containing the BSAWarfarin mixture (1:1). These mixtures were allowed to stand for 10 minutes for allowing binding of the warfarin to its particular binding site. From each of the test tube, 3.5 mL solution was taken and poured into six different semi-permeable membrane tubes. Two ends of the membrane tube were folded and fixed with thread to ensure that there was no leakage. The membrane tubes were then immersed in six separate 50 mL conical flasks containing 20 mL of phosphate buffer solution of pH 7.4. The conical flasks were then placed in a water bath shaker for dialysis at 37°C and 20 rpm and shaking was continued for about 12 hours. After completion of dialysis, samples were collected from each flask. Then the samples were filtered with syringe filter and the free concentrations of warfarin and amlodipine besylate were measured by validated HPLC technique.
Determination of binding site of amlodipine besylate using diazepam as a site-II specific probe
Bind site of amlodipine besylate using diazepam as a site-II specific probe was determined by using the same method as mentioned above. M) was added with increasing concentrations into four out of five test tubes containing 1:1 mixture of BSA-Warfarin. The final ratios between benazepril hydrochloride and protein were 1:1, 2:1, 4:1 and 6:1 and made the final volume by respective buffer solution. Benazepril hydrochloride was not added in the one test tube containing the BSA-Warfarin mixture (1:1). These mixtures were allowed to stand for 10 minutes for allowing binding of the warfarin to its particular binding site. The solutions were then properly mixed and allowed to stand for 10 minutes in order to ensure maximum binding of warfarin and benazepril hydrochloride to BSA. From each of the test tube, 3.5 mL of solution was taken and poured into six different semi-permeable membrane tubes. Two ends of the membrane tube were folded and fixed with thread to ensure that there was no leakage. The membrane tubes were then immersed in six separate 50 mL conical flasks containing 20 mL of phosphate buffer solution of pH 7.4. The conical flasks were then placed in a water bath shaker for dialysis at 37°C and 20 rpm and shaking was continued for about 12 hours. After completion of dialysis, samples were collected from each flask. Then the samples were filtered with syringe filter and the free concentrations of Warfarin and Benazepril Hydrochloride were measured by HPLC technique.
Determination of binding site of benazepril hydrochloride using diazepam as a site-II specific probe
Binding site of Benazepril Hydrochloride using Diazepam as a site-II specific probe was determined by using the same method as mentioned above. Two end of the membrane tube were folded and fixed with thread to ensure that there was no leakage. The membrane tubes were then immersed in five separates 50 mL conical flasks containing 20 mL of phosphate buffer solution of pH 7.4.The conical flasks were then placed in a waterbath shaker for dialysis at 37 0 C and 20 rpm and shaking was continued for 12 hours. After completion of dialysis, samples were collected from each flask. The samples were filtered through syringe filter and the free concentrations of amlodipine besylate and benazepril hydrochloride were measured by HPLC analytical method.
RESULTS AND DISCUSSION
Equations for standard curves are presented in table 1. Equations are utilized to calculate the value of free drug concentration. Determining association constant and number of binding sites Drug-protein binding are mainly of two types -strong affinity binding to a smaller number of sites and weak affinity binding to a large number of sites (kabir et al., 2010) . In this present experiment, the binding parameters of amlodipine besylate and benazepril hydrochloride have been characterized by scatchard plot. The non-linear curve of plot confirmed the presence of at least two classes of binding sites of experimental drugs to BSA.
By non-linear curve (scatchard plot analysis) of equilibrium dialysis data from table 2, showed that at pH 7.4 and 37 °C association constant and number of bonding site of amlodipine besylate are about 8.47 x 10 5 M -1 and 1.9, respectively at high affinity binding site. On the contrary, at low affinity binding site, association constant and number of binding site were found about 0.33 x10 5 M -1 and 11.7 respectively (Fig. 1 ). By non-linear curve (scatchard plot analysis) of equilibrium dialysis data from table 3 showed that at pH 7.4 and 37 °C association constant and number of binding sites of benazepril hydrochloride are about 14 x 10 5 M -1 and 1, respectively at high affinity binding site. On the other hand, at low affinity binding site, association constant and number of binding site were found about 0.31 x10 5 and 16 respectively (Fig. 2) .
So, the non-linear curves showed the presence of at least two classes of binding sites for the binding of amlodipine besylate and benazepril hydrochloride to BSA.
Determining binding sites of amlodipine besylate and benazepril hydrochloride on BSA
Binding sites of amlodipine besylate and benazepril hydrochloride were determined by calculating their ability to displace of warfarin sodium and diazepam. The basic principle is that, if a drug is able to displace a probe from its binding site, it is assumed that the drug also binds to that particular site (Alam et al., 2009) . Displacement of warfarin sodium (Table 4 ) and diazepam (Table 5) M, free warfarin sodium was increased from 100 to 500%. On the other hand free concentration of diazepam was increased from 100 to 166.2%. These findings indicate that addition of amlodipine besylate displaces more warfarin sodium than diazepam. So it can be concluded that amlodipine besylate preferentially binds to Site-I. Similar result was also found previously by other researchers (Alam et al., 2008; Alam et al., 2011) . Free fraction of amlodipine besylate remained almost same (7.8 to 9.4%) with the addition of Benazepril HCl from 2 x 10 M in the mixture of benazepril hydrochloride and BSA (1:1). So concurrent administration of these two drugs will not alter the therapeutic efficacy of each other.
CONCLUSION
It can be assumed that the experimental drugs amlodipine besylate and benazepril hydrochloride preferentially bind with Site-I and Site-II respectively. In addition to Site-I, amlodipine besylate also binds with site-II on the BSA molecule but to a lower extent. As, the investigated drugs compete for different site (Site-I amlodipine besylate and site-II benazepril hydrochloride), concurrent administration of these two drugs will not alter the therapeutic efficacy of each other. Hence the combination dosage form of these two drugs will be of therapeutic value as a single dosage form in hypertension.
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